Full-Time

Director – Pharmacometrics

Confirmed live in the last 24 hours

Vir Biotechnology

Vir Biotechnology

501-1,000 employees

Develops monoclonal antibodies for infectious diseases

AI & Machine Learning
Biotechnology

Compensation Overview

$194.5k - $284kAnnually

Senior, Expert

No H1B Sponsorship

San Francisco, CA, USA

Requires onsite presence in San Francisco for four days per week.

Category
Computational Biology
Biology Lab & Research
Biology & Biotech
Required Skills
R
Requirements
  • PhD with at least 10 years of experience OR MS degree with at least 13 years of experience
  • Educational background in biopharmaceutics, pharmaceutical sciences, pharmacometrics, mathematics, statistics or biostatistics.
  • Experience with quantitative modeling including performing population PK/PKPD analyses using standard pharmacometric software (e.g. NONMEM, R, Monolix, Phoenix) for protein therapeutics (e.g. mAbs, siRNA) and small molecule therapeutics.
  • Experience managing MIDD (model informed drug development) regulatory strategies together with clinical pharmacology project leads to achieve desired outcomes.
  • Experience with quantitative systems pharmacology (QSP) and physiologically based pharmacokinetic (PBPK) modeling
  • Experience with clinical pharmacology studies to support intrinsic/extrinsic factors and the ability to author and defend pharmacometrics components of regulatory filings.
  • Lead modeling and simulations activities with external CROs.
  • Mentor junior staff within Clinical Pharmacology.
Responsibilities
  • Working in collaboration with the Project Lead Clinical Pharmacologist you will develop and implement model informed drug development (MIDD) plans across projects and disease areas to optimize prospective studies and inform drug development strategy and project decision-making.
  • With the Project Lead Clinical Pharmacologist you will be responsible for pharmacometrics activities including population pharmacokinetics modeling and simulations, PK/PD and exposure-response.
  • Conduct modeling and simulations activities for programs across multiple stages of development, from pre-IND through post-marketing.
  • Present modeling and simulation data as a technical pharmacometrics expert on cross-functional project sub-teams.
  • Identify opportunities where modeling and simulation can promote the understanding of pharmacological activity, efficacy and safety.
  • Provide support and help develop our quantitative methodology, pharmacometrics tools, software, hardware, and related business processes.

Vir Biotechnology develops treatments for infectious diseases by harnessing the immune system, using a proprietary platform for monoclonal antibodies (mAbs) combined with machine learning and artificial intelligence. Their pipeline includes clinical candidates for hepatitis B, hepatitis delta, and HIV, as well as monoclonal antibodies targeting influenza, COVID-19, and human papillomavirus. What distinguishes Vir from competitors is its collaboration with industry leaders and organizations to expedite scientific advancements. The company's goal is to transform lives by addressing unmet medical needs.

Company Stage

Grant

Total Funding

$640.6M

Headquarters

San Francisco, California

Founded

2016

Growth & Insights
Headcount

6 month growth

2%

1 year growth

5%

2 year growth

8%
Simplify Jobs

Simplify's Take

What believers are saying

  • Recent bullish quarterly reports and increased analyst estimates suggest strong financial performance.
  • Significant investments, such as the $214,000 from Diversified Trust Co, indicate confidence in Vir's future prospects.
  • Presentations at high-profile conferences like J.P. Morgan's Annual Healthcare Conference and AASLD's The Liver Meeting® enhance Vir's visibility and credibility in the biotech community.

What critics are saying

  • Recent layoffs and facility shutdowns indicate potential financial instability and operational challenges.
  • The resignation of key executives, including the CFO and Chief Medical Officer, could lead to strategic and leadership uncertainties.

What makes Vir Biotechnology unique

  • Vir Biotechnology's focus on leveraging immunology expertise to engineer human antibodies into powerful medicines sets it apart from competitors.
  • Their rapid growth, as evidenced by being ranked the fastest-growing company in North America on the 2023 Deloitte Technology Fast 500, highlights their market impact.
  • Vir's ongoing Phase 2 trials for chronic hepatitis delta and B demonstrate their commitment to addressing unmet medical needs with innovative therapies.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Comprehensive healthcare coverage

Employer matched 401(k)

Employee stock purchase plan

Childcare assistance

Tuition reimbursement